Spotlight Series on Hepatitis C


Closing the Gap for Tough-to-Treat Hepatitis C Patients

November 22, 2016


Closing the Gap for Tough-to-Treat Hepatitis C Patients

When sofosbuvir (Sovaldi) was approved in 2013, it was celebrated for high cure rates, but it wasn't perfect for every patient with hepatitis C. By 2016, a slew of new medicines closed the gap for the vast majority of those tough-to-treat patients, including patients with any genotype or fibrosis level, or coinfection with HIV.

Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. These include patients with genotype 3 infection plus liver damage, patients who have failed prior treatment or developed resistance and patients with decompensated cirrhosis.

At the recent Liver Meeting in Boston, Nancy Reau, M.D., section chief, Hepatology, Rush University Medical Center, presented a summary of soon-to-be-approved drugs that should work for this "handful" of groups.

Get Started

Credit: ribkhan for iStock via Thinkstock.

This article was provided by It is a part of the publication The Liver Meeting.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.